The total return over the past 12 months is +66.22% vs. +16.94% for the S&P 500. So far it's up +30.77% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +66.22% | (23.50%) | (39.51%) | N/A | N/A | N/A |
| Total Return CAGR | +66.22% | (23.50%) | (39.51%) | N/A | N/A | N/A |
| Revenue CAGR | (56.25%) | (7.02%) | +19.13% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Sutro Biopharma, Inc. (STRO)
| Year | Start price | End price | STRO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $11.57 | $15.13 | +30.77% | +14.51% | +16.26% |
| 2025 | $18.40 | $11.57 | (37.12%) | +17.72% | (54.84%) |
| 2024 | $42.90 | $18.40 | (57.11%) | +24.89% | (82.00%) |
| 2023 | $80.80 | $42.90 | (46.91%) | +26.19% | (73.10%) |
| 2022 | $148.80 | $80.80 | (45.70%) | (18.17%) | (27.53%) |
| 2021 | $217.10 | $148.80 | (31.46%) | +28.74% | (60.20%) |
| 2020 | $110.00 | $217.10 | +97.36% | +18.37% | +78.99% |
| 2019 | $90.20 | $110.00 | +21.95% | +31.22% | (9.27%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
